

University of Kentucky Office of Research Integrity and Institutional Review Board Standard Operating Procedures			
SOP #3-4 Revision #2	TITLE: Humanitarian Use Device (HUD)		Page 1 of 5
Approved By: ORI Director	Signature	Date	Date First Effective: 07-24-06
Approved By: Nonmedical IRB Chair	Signature	Date	
Approved By: Medical IRB Chair	Signature	Date	Revision Date: 07-31-09

OBJECTIVE

To describe the process for Institutional Review Board (IRB) review of a humanitarian use device (HUD) including clinical, emergency, compassionate, and investigational use

GENERAL DESCRIPTION

The University of Kentucky (UK) Medical IRBs may approve the following situations involving HUDs:

- Clinical use of a HUD as a legally marketed device; OR
- Emergency or compassionate use of a HUD based on a healthcare provider/principal investigator (PI) request that meets IRB criteria; OR
- Investigational use for research purposes either consistent with approved labeling or off-label.

Definitions

A *Humanitarian Use Device* is a medical device intended to benefit patients in the treatment or diagnosis of a disease or condition that affects or is manifested in fewer than 4,000 individuals in the United States per year.

The term *Use* refers to use of a HUD according to its approved labeling and indications.

The term *Investigational Use* refers to research involving a HUD.

A *Humanitarian Device Exemption* (HDE) is a Food and Drug Administration (FDA) marketing application that is similar to a premarket approval application but is exempt from the effectiveness requirements of the medical device law, provided the device meets safety conditions and will not expose patients to significant or unreasonable risk. An HDE approval is based on safety and probable benefit.

University of Kentucky Office of Research Integrity and Institutional Review Board Standard Operating Procedures		
SOP #3-4 Revision #2	TITLE: Humanitarian Use Device (HUD)	Page 2 of 5

An *Investigational Device Exemption* (IDE) refers to the regulations under 21 CFR 812. An approved IDE means that the IRB (and FDA for significant risk devices) has approved the sponsor's study application, and the proposed use meets all the requirements of 21 CFR 812.

RESPONSIBILITY

Execution of SOP: IRB, IRB Chair, IRB Vice Chair, IRB Members, Office of Research Integrity (ORI) Staff, Principal Investigator (PI)/Study Personnel, Healthcare Providers

PROCEDURES

HUD Clinical Use for Treatment or Diagnosis Consistent with Approved Labeling

1. The healthcare provider responsible for the use of the HUD submits an IRB application to the ORI in accord with the Initial Full Review SOP. He/she obtains IRB approval before use.
2. The full Medical IRB reviews clinical use of a HUD in a convened meeting using all standard full review criteria and procedures. The IRB approves the use of the HUD device consistent with the scope of the FDA-approved indications for groups of patients meeting clinical criteria.
3. The IRB may choose to require informed consent that is consistent with the approved labeling or allow use of a modified clinical consent or operative permit.
4. The healthcare provider seeks and the Medical IRB provides continuing review using standard criteria and procedures. The IRB may use expedited review procedures for continuing review.
5. The healthcare provider submits a report to FDA and to the IRB whenever a HUD may have caused or contributed to a death or serious injury or has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur (21 CFR 814.126(a)).

HUD Emergency Use

1. The healthcare provider submits an emergency use request to the ORI in accord with the Emergency Use SOP.
2. The Medical IRB, IRB Chair, Vice Chair, or medically qualified IRB member approves requests for emergency use of a HUD in a single subject when there is no time to use the existing FDA approval procedures for compassionate use and the use meets the following criteria prior to the device use:

University of Kentucky Office of Research Integrity and Institutional Review Board Standard Operating Procedures		
SOP #3-4 Revision #2	TITLE: Humanitarian Use Device (HUD)	Page 3 of 5

- The healthcare provider must obtain approval from the sponsor of the HDE (either a sponsor or a physician);
 - The healthcare provider must certify in writing in the patient chart that:
 - The patient has a life-threatening condition, OR;
 - The patient has a serious medical condition that can reasonably be expected to benefit from the use of the HUD, AND;
 - This is the best acceptable treatment alternative for the patient; AND;
 - Alternative treatments pose greater risks for the patient or are deemed to provide less benefit than the HUD.
3. The healthcare provider obtains and documents in the patient chart a corroborative opinion about the benefit of the HUD for the intended patient from an independent physician who is qualified in the appropriate medical specialty.
 4. The healthcare provider provides the HDE holder and the Medical IRB with information addressing the criteria listed in item 2.
 5. The healthcare provider obtains informed consent from the patient or the patient's legally authorized representative using the IRB-approved consent form or modified clinical consent or operative permit.
 6. If the healthcare provider proposes to administer the test article in emergency use situations without informed consent, the request to the IRB Chair includes a statement certifying in writing that the proposed use meets all of the conditions listed in 21 CFR 50.23.
 7. For emergency use of a HUD, the healthcare provider assumes the responsibilities of the HDE holder, monitors the patient, and reports the use of the HUD, including any safety-related information to FDA or the HDE holder.
 8. The healthcare provider submits a report to FDA and to the IRB whenever a HUD may have caused or contributed to a death or serious injury or has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur (21 CFR 814.126(a)).

HUD Compassionate Use

1. The healthcare provider submits an IRB application to the ORI.
2. In the title of the application on the General Information Sheet, the healthcare provider includes the words: "Compassionate Use HUD."

University of Kentucky Office of Research Integrity and Institutional Review Board Standard Operating Procedures		
SOP #3-4 Revision #2	TITLE: Humanitarian Use Device (HUD)	Page 4 of 5

3. The UK IRB may, at its discretion, approve a healthcare provider's application for the compassionate use of a HUD when the proposed use meets the following criteria:
 - The healthcare provider has determined that there is no alternative device for the patient's condition, and there is no emergency.
 - The healthcare provider has provided the HDE holder and the Medical IRB with the following:
 - A description of the patient's condition and the circumstances necessitating treatment with the device;
 - A discussion of why alternative treatments are unsatisfactory; and
 - Assurances and information about patient protection measures.
4. The healthcare provider provides the HDE holder and the Medical IRB with information addressing the criteria listed in item 3.
5. In addition, the healthcare provider requests that the HDE holder submit an HDE amendment for FDA approval prior to the compassionate use of the device. If the FDA grants approval, the healthcare provider reports the use of the HUD to the IRB and the HDE holder for subsequent submission to the FDA database.
6. The full IRB reviews compassionate use in a convened meeting using all standard full review criteria and procedures. The approval applies to the single case requested and does not apply to a class of patients.
7. The healthcare provider obtains informed consent from the patient or the patient's legally authorized representative using the IRB-approved consent form or modified clinical consent or operative permit.
8. The healthcare provider monitors the patient and submits a follow-up report including any safety-related information to the FDA or the HDE holder.
9. The healthcare provider submits a report to FDA and to the IRB whenever a HUD may have caused or contributed to a death or serious injury or has malfunctioned and would be likely to cause or contribute to a death or serious injury if the malfunction were to recur (21 CFR 814.126(a)).

HUD Investigational Use Consistent with Labeling

1. The UK IRB may, at its discretion, approve a PI's application for the investigational use of a HUD device to collect safety and effectiveness data consistent with the scope of the FDA-approved indications.
2. The PI submits an IRB application to the ORI, and the IRB reviews and approves the study in accord with the Initial Full Review SOP.

University of Kentucky Office of Research Integrity and Institutional Review Board Standard Operating Procedures		
SOP #3-4 Revision #2	TITLE: Humanitarian Use Device (HUD)	Page 5 of 5

3. The PI conducting an investigation of a HUD according to its approved labeling and indication must obtain IRB approval and informed consent consistent with all FDA-regulated clinical studies. Hospital consents or operative permits are not sufficient for investigational use.

HUD Off-Label Investigational Use

1. The UK IRB may, at its discretion, approve a PI's application for the investigational use of a HUD device beyond its approved indication(s) when the proposed use is in compliance with 21CFR 812 requiring an IDE if there is significant risk.
2. The PI submits an IRB application to the ORI, and the IRB reviews and approves the study in accord with the Initial Full Review SOP and the Medical Device SOP.
3. The ORI and IRB follow procedures outlined in the Medical Device SOP for IRB review of significant risk and non-significant risk investigational device use. (See Medical Device SOP.)
4. If the HUD carries significant risk, the PI may conduct the study following FDA approval of an IDE application.
5. The PI obtains informed consent consistent with all FDA-regulated clinical studies. Hospital consents or operative permits are not sufficient for investigational use.

REFERENCES

Food and Drug Administration

Draft Guidance for HDE Holders, Institutional Review Boards, Clinical Investigators, and FDA Staff – Humanitarian Device Exemption (HDE) Regulation: Questions and Answers (August 2008)

Information Sheet Guidance: Frequently Asked Questions about Medical Devices (January 2006)

21 CFR 812.35(a)

21 CFR 814.24

21 CFR 50.23